Annals of Family Medicine

NOVEMBER 20, 2024

Study Design and Analysis This study utilized data from NHANES 2011-2019 to calculate two ASCVD risk scores for each eligible individual: one using the race-based PCE and the other using the race-agnostic PREVENT equation. Each individual was separated into clinically significant risk categories of <7.5%, 7.5-10%,

Individual 130

Individual Utilities Clinic Provider 130

Annals of Family Medicine

NOVEMBER 20, 2024

Data for this investigation were sourced from a community-based approach, utilizing information from CHS, which integrates data from community sources and hospitals. Population: Jewish CHS members, aged 18+, diagnosed with T2D between 2000-2011, born in Israel or Ethiopia. Intervention: 10-year follow-up to track T2D outcomes.

Complication 130

Complication Diabetes Individual Chronic Disease 130

Today's Hospitalist

MAY 9, 2025

Since the mid-1990s, our capacity for innovation has never stopped as hospitalists navigate a complex landscape of acute illnesses, interprofessional collaborations and the imperative to provide efficient, high-quality care. We have seen explosive growth and become a cornerstone of modern health care systems.

Patient-Centered 52

Patient-Centered Telemedicine Clinic Electronics 52

FDA Law

MAY 27, 2024

Jennifer’s combination of experiences as in-house counsel for both large and start-up companies as well as outside counsel provides clients invaluable expertise and problem-solving skills. Jennifer was with the firm from 2011-2017, before leaving for in-house roles at Apple, Abbott Laboratories, and Cognito Therapeutics.

Manufacturing 59

Manufacturing Management Utilities Relationship 59

FDA Law

NOVEMBER 6, 2022

2011), here , and United States v. The Court found that there is at best little utility in interpreting the AKS by reference to the BIS. As Pfizer has argued throughout this legal battle, its proposed copay assistance program “poses no risk of corrupting independent decision making” or of inducing improper utilization of tafamidis.

Manufacturing 83

Manufacturing Patient-Centered Healthcare Utilities 83

FDA Law

SEPTEMBER 11, 2023

In 2011, the Institute of Medicine released a report recommending elimination of the 510(k) process altogether ( link ), noting an inherent conflict between the legislative framework and FDA’s stated goals to protect patients and promote innovation in support of public health.

Medical 64

Medical Electronics Manufacturing Utilities 64

The Clinical Problem Solvers

DECEMBER 16, 2020

Our esteemed publications should ensure that investigations that utilize racial variables follow these guidelines before being published. Examining the Potential Impact of Race Multiplier Utilization in Estimated Glomerular Filtration Rate Calculation on African-American Care Outcomes. 2011 Sep 20;155(6):408]. doi:10.1001/jama.2019.577

Clinic 52

Clinic Education Clinical Practice Patient-Centered 52